|
![]() |
|||
|
||||
OverviewFull Product DetailsAuthor: Rolf Voges , J. Richard Heys , Thomas Moenius (Novartis Pharma)Publisher: John Wiley & Sons Inc Imprint: John Wiley & Sons Inc Dimensions: Width: 17.40cm , Height: 4.30cm , Length: 25.20cm Weight: 1.279kg ISBN: 9780470516072ISBN 10: 0470516070 Pages: 688 Publication Date: 20 March 2009 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Out of stock ![]() The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available. Table of ContentsReviewsAuthor InformationRolf Voges studied chemistry at the Universities of Marburg and Freiburg, where he received his Ph.D. in organic chemistry on investigations into steric isotope effects, for which he received the Go¨deke Award. After postdoctoral research on stereoselective syntheses he joined the isotope group of Sandoz Pharma AG (now Novartis AG) being involved for thirty years in organic radiochemical synthesis as Head of the Isotope Laboratories and then Head of Isotope Section. He is author or coauthor of about 40 publications, one patent, and coeditor of two previous conference proceeding volumes in the field, co-organizer of two international symposia on the synthesis and application of isotopically labeled compounds, founder and co-organizer of eleven Bad Soden meetings of the Central European Division of the International Isotope Society (CED-IIS), and co-editor of the proceedings. For three years he held a leadership position in the IIS, serving as its 2001 president. In recognition of his scientific achievements and his service to the isotope society he received the IIS-CED Award in 1995 and in 2003 the IISAward. He is now retired and lives in southwestern Germany, near the Swiss and French borders. Richard Heys received his Ph.D. in organic chemistry from Stanford University in 1976 and conducted postdoctoral research in the chemistry department at Yale; both involved the synthesis of radiolabeled compounds and their use in elucidation of biosynthetic pathways. His subsequent 29-year career in organic radiochemical synthesis both in the laboratory and as a manager took him to the Radiochemistry Department of Midwest Research Institute (now part of Aptuit, Inc.), Smith Kline & French Laboratories/SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and AstraZeneca Pharmaceuticals. Author or coauthor of over 85 publications, 8 patents and a previous conference proceedings volume in the field, organizer of an international symposium on the synthesis of isotopically labeled compound and holder of leadership positions (including president and CFO) in the International Isotope Society for 9 years, he is retired and lives in northwestern Connecticut. Thomas Moenius received his Ph.D. in organic chemistry from the University of Erlangen-Nu¨rnberg in 1986. He is a member of the isotope group of Novartis Pharma AG, working in the field of carbon-14 and tritium labeling. Since 2007 he is also European Editor for Journal for Labelled Compounds and Radiopharmaceuticals. Tab Content 6Author Website:Countries AvailableAll regions |